A multicenter, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant when added to ongoing lipid-modifying therapy in dyslipidemic patients deemed appropriate for further lipid modification.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant when added to ongoing lipid-modifying therapy in dyslipidemic patients deemed appropriate for further lipid modification.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2015

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 16 Jul 2008 Status changed from initiated to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Planned start date for this trial is Sep 2008 as reported by ClinicalTrial.gov
    • 12 Jun 2008 The expected completion date for this trial is extended from Jul 2009 to Nov 2009 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top